Effects of Cholecystokinin Receptor Agonist and Antagonists on Morphine Dependence in Mice

Zarrindast, Mohammad‐Reza; Malekzadeh, Anahita; Rezayat, Mehdi; Ghazi-Khansari, Mahmood

doi:10.1111/j.1600-0773.1995.tb01042.x

Cited by 16 publications

(11 citation statements)

References 34 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This effect also appears to be mediated by CCK A receptors. Data from in vivo studies have shown that both CCK agonists and antagonists reduce naloxone‐precipitated withdrawal signs in morphine‐dependent mice ( Zarrindast et al ., 1995 ). Similar conflicting results come also from antinociception studies (reviewed by Cesselin, 1995 ).…”

Section: Discussionmentioning

confidence: 99%

“…Earlier evidence that daily administration of CCK antagonists left the withdrawal syndrome in morphine‐dependent animals unaffected ( Dourish et al ., 1988 ; Panerai et al ., 1987 ; Xu et al ., 1992 ) and that CCK agonists did not precipitate a withdrawal syndrome in dependent animals ( Maldonado et al ., 1994 ; Pournaghash & Riley, 1991 ) suggested that the development or expression of physical dependence did not involve CCK systems. However, later works showed that CCK agonists reduced or prevented the withdrawal signs precipitated by naloxone in morphine‐dependent mice ( Zarrindast et al ., 1995 ; Rezayat et al ., 1997 ). On the other hand, a CCK B receptor antagonist potentiated the inhibition of morphine withdrawal of an inhibitor of enkephalin catabolism ( Maldonado et al ., 1995 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interactions between cholecystokinin and opioids in the isolated guinea‐pig ileum

Romanelli

Amico

Mattioli

et al. 1999

British J Pharmacology

View full text Add to dashboard Cite

1 Although cholecystokinin octapeptide sulphate (CCK-8) activates the opioid system of isolated guinea-pig ileum (GPI) whether it activates the m-or k-system, or both, remains unclear. Neither is it known whether CCK-8 in¯uences the withdrawal responses in GPI preparations brie¯y exposed to opioid agonists. This study was designed to clarify whether CCK-8 activates m-or k-opioid systems or both; and to investigate its eect on the withdrawal contractures in GPI exposed to m-or kagonists and on the development of tolerance to the withdrawal response. 2 In GPI exposed to CCK-8, the selective k-antagonist nor-binaltorphimine elicited contractile responses that were concentration-related to CCK-8 whereas the selective m-antagonist cyprodime did not. 3 In GPI preparations brie¯y exposed to the selective m-agonist, dermorphin, or the selective kagonist, U-50, 488H, and then challenged with naloxone, CCK-8 strongly enhanced the withdrawal contractures. 4 During repeated opioid agonist/CCK-8/opioid antagonist tests tolerance to opioid-induced withdrawal responses did not develop. 5 These results show that CCK-8 preferentially activates the GPI k-opioid system and antagonizes the mechanism(s) that control the expression of acute dependence in the GPI.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Interactions between cholecystokinin and opioids in the isolated guinea‐pig ileum

Romanelli

Amico

Mattioli

et al. 1999

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…On day 4, a single dose of morphine (50 mg/kg) was injected 2 h before naloxone treatment. Each mouse received ten doses of morphine (Hosseinzadeh and Lary, 2000;Zarrindast et al , 1995).…”

Section: Preliminary Chemical Testsmentioning

confidence: 99%

“…After the naloxone challenge, mice were immediately placed in a glass cylinder (30 cm high, 20 cm in diameter). The number of jumps was recorded for 30 min after naloxone (NXL) injection (Hosseinzadeh and Lary, 2000;Zarrindast et al , 1995).…”

Section: Preliminary Chemical Testsmentioning

confidence: 99%

Effect of Rosmarinus ofﬁcinalis L. aerial parts extract on morphine withdrawal syndrome in mice

Hosseinzadeh

Nourbakhsh

2003

Phytotherapy Research

View full text Add to dashboard Cite

The effect the aqueous and ethanol extracts of Rosmarinus officinalis L. aerial parts on morphine withdrawal syndrome was investigated in mice. The aqueous and ethanol extracts induced a significant antinociceptive activity in the writhing test. This activity was inhibited by naloxone pretreatment. Dependence was induced using subcutaneous injections of morphine daily for 3 days. On day 4, morphine was injected 2 h prior to the intraperitoneal injection of naloxone. The number of jumps during the 30 min period after naloxone injection was considered as a measure of the withdrawal syndrome. The results indicated that the aqueous (1.68 g/kg and 2.4 g/kg, i.p.) and ethanol (0.96 g/kg, i.p.) extracts reduced the number of jumps. Phytochemical study indicated that only the aqueous extract of R. officinalis has an alkaloid component. It is concluded that the aqueous and ethanol extracts of R. officinalis aerial parts could diminish morphine withdrawal syndrome.

show abstract

“…All the drugs were administered subcutaneously. The doses of the drugs were based on previous studies (Dourish et al 1988;Rezayat et al 1994;Zarrindast et al 1995Zarrindast et al & 1997.…”

Section: Methodsmentioning

confidence: 99%

Role of Cholecystokinin Receptors in Induction of Antinociception in Hot‐Plate Test

Rezayat

Rahnavard

Zarrindast³

2000

Pharmacology & Toxicology

Self Cite

View full text Add to dashboard Cite

In the present study, the antinociceptive effect of cholecystokinin receptor agonists in the hot-plate test in mice has been evaluated. Subcutaneous administration of cholecystokinin octapeptide (cholecystokinin-8; 0.001, 0.005, 0.01, 0.05, and 0.1 mg/kg), unsulfated cholecystokinin octapeptide (cholecystokinin-8U; 0.1 mg/kg) or caerulein (0.25 mg/kg) produced antinociception. Administration of the cholecystokinin tetrapeptide (cholecystokinin-4; 0.25, 0.5 and 1.0 mg/ kg) had no effect in the hot-plate test. Subcutaneous injection of the selective cholecystokinin receptor antagonists, MK-329 (0.125, 0.25 and 0.5 mg/kg) or L-365,260 (0.125, 0.25 and 0.5 mg/kg), produced no antinociceptive response. When the animals were pretreated with the cholecystokinin receptor antagonists or naloxone (0.5 and 1 mg/kg), a significant decrease in the antinociceptive response induced by cholecystokinin-8 and caerulein was obtained. The results indicate that single administration of cholecystokinin receptor agonists could produce an antinociceptive effect which is probably mediated via cholecystokinin receptors. With respect to the results obtained from morphine and naloxone administration, it is concluded that there may be an interaction between cholecystokinin and opiate mechanisms.The peptide, cholecystokinin, is found in the mammalian nervous system (Vanderhaeghen et al. 1975;Rehfeld 1978;Faris et al. 1983). Caerulein is closely related to the naturally occurring cholecystokinin-8 (Rehfeld & Hansen 1984;Baber et al. 1989). Cholecystokinin-8 and related peptides produce several neural-mediated effects after both peripheral and central administration (Zelter 1982;Baber et al. 1989). Cholecystokinin-like immunoreactivity has been described in areas of the spinal cord and brain which are believed to play a role in nociception. Sulfated cholecystokinin-8 and the small amounts of cholecystokinin-4 are thought to be present in many regions of the midbrain including the periaqueductal gray and substantia nigra, which are important areas in pain modulation (Baber et al. 1989). Exogenously applied cholecystokinin-8 and related peptides have produced different results on pain modulation in rodents (Wiesenfeld-Hallin et al. 1990). Cholecystokinin-8 has been found to reduce the analgesic effect of the morphine and b-endorphin (Itoh et al. 1982). Our previous results also show that pretreatment of mice with cholecystokinin receptor agonist (Cesselin 1995) decreased or increased the morphine-induced antinociception depending on pretreatment time . There is also evidence indicating that the cholecystokinin mechanism may play an important role in pain transmission by modulating CNS opiate mechanisms (Jurna & Zetler 1981;Suh et al. 1992). It has also been suggested that there may be multiple 1986). The highly selective and potent cholecystokinin-A receptor antagonists, MK-329 and L-365,260 are now available, which opens the possibility to evaluate the role of cholecystokinin receptor types in mechanism of pain system (Wiesenfeld-Hal...

show abstract

Effects of Cholecystokinin Receptor Agonist and Antagonists on Morphine Dependence in Mice

Cited by 16 publications

References 34 publications

Interactions between cholecystokinin and opioids in the isolated guinea‐pig ileum

Interactions between cholecystokinin and opioids in the isolated guinea‐pig ileum

Effect of Rosmarinus ofﬁcinalis L. aerial parts extract on morphine withdrawal syndrome in mice

Role of Cholecystokinin Receptors in Induction of Antinociception in Hot‐Plate Test

Contact Info

Product

Resources

About